Providence Cancer Center’s Dr. Rachel Sandborn conducted one of two clinical trials that resulted in successful treatment of the most common type of lung cancer. The trials enrolled patients with advanced squamous non-small cell lung cancer, which is incurable. The breakthrough drug, Opdivo, targets the protein PD-1, which certain cancer cell use to makes themselves from the immune system. By attacking PD-1, Opdivo unveils the cancer cells so they’re exposed, letting the immune system do its work. More information.